Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II Clinical Study Investigating the Addition of Bevacizumab to Carboplatin and Weekly Paclitaxel as First-line Treatment in Patients With Epithelial Ovarian Cancer

NCT00937560 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00937560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00937560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II Clinical Study Investigating the Addition of Bevacizumab to Carboplatin and Weekly Paclitaxel as First-line Treatment in Patients With Epithelial Ovarian Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
June 25, 2009
Completion date
July 1, 2013
Enrollment
190 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer